

IR Letter

2022. 05. 11.

Jeisys

(KQ : 287410)

96, Gamasan-ro, Geumcheon-gu,
Seoul, Korea

Disclaimer

▶ it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

· We announced earning results for the first-quarter 2022 on May 11, 2022

· It recorded KRW 25.3bn (YoY 47%) in sales and KRW 8.5bn (YoY 73%)
in operating profit in the first quarter

Seoul, May 11, 2022 _ Jeisys Medical inc. reported earning results for the first-quarter 2022 on May 11, 2022

We believe that the global medical aesthetics market has been constantly growing and our product portfolio including RF, HIFU and consumables has been growing on higher demand in global market.

In addition, we commit to achieve continuous growth through business activities such as its partnership with Cynosure, expanding distribution in Japanese subsidiary, and launching new products.

1Q 2022 Summary

1. Sales : Sales increased in the entire product portfolio and it recorded KRW 25.3bn (YoY 47%)
2. Gross profit : As increasing sales significantly, it reached KRW 17.7 bn (YoY 41%) in gross profit and its gross profit ratio was 70%
3. Operating profit : With high sales growth, the SG&A ratio decreased and an operating profit reached KRW 8.5bn (YoY 73%) and its operating profit ratio was 34%
4. Net profit : With high sales growth and cost control, the net profit reverted to a surplus of KRW 6.5bn and its operating profit ratio was 26%

I. Sales


In the first quarter 2022, the global medical aesthetics market has been constantly growing and our entire product portfolio have been in the spotlight in the global market. As a result, It recorded KRW 25.3 bn in sale and rose by 46.8% in the same period since last year and 3.9% compared to the previous quarter.

① Sales by product portfolio

Device sales including the entire product portfolio reached high sales growth.

Sales by product portfolio were RF 27.9%, HIFU 14.3%, IPL 4.9%, LASER 9.9%, Consumables 40.4%, Other 2.7%.

- RF (YoY 77.6%) : the strong RF demand trend and increasing POTENZA ODM in North America
- HIFU (YoY 9.8%) : Due to lower demand prior to launch new product which scheduled for the second quarter of 2022 sales by major countries including japan decreased but the order for ULTRACel Q+ increased in other countries including Southeast Asia as reduction covid-19 spread.
- IPL (YoY 140.3%) Overseas sales of Celtec increased
- LASER (YoY 57.3%) : Overseas sales of TRI-BEAM, Edge ONE increased
- Consumable (YoY 41.0%) : Due to higher demand for consumables with various functions as growing medical aesthetic procedure in global, both catridges and tips sales increased.



② Sales by Regional

Both domestic and overseas sales achieved higher growth in the same period since last year.

The proportion of sales by region was 13.5% domestic and 86.5% overseas.

- Domestic (YoY 39.6%)

- Due to lower demand prior to launch new device, HIFU(LinearFirm) sales decreased slightly but RF(POTENZA) sales has increased since last year as well as IPL and Laser sales
 - Consumables have increased sales for both Cartridge and Tip as procedures increases.
- In particular, Cartridge sales increased YoY 133%, leading to domestic sales along with RF



- Overseas (YoY 48.0%)

Japan

- Due to lower demand prior to launch new product, HIFU(ULTRACel Q+) sales decreased slightly.
- As an expansion of entering aesthetic clinics, RF sales has constantly increased since last year.
- Consumables sales including cartridges and tips have increased by growing medical aesthetic procedures. Especially, Tips sales has increased by 330% in the same period since last year by increasing the sales of POTENZA

ODM



- As renewal agreement with Cynosure in March 2022, supplies rose by 61% compared to the same time last year (retroactive application from November 2021).
- Continuous sales growth after successful launch in US market since 2020
- Consumables sales increased (124% YOY) as increasing device Installation and the higher demand for tips with various functions gradually.



II. Gross profit

Due to the high sales growth, it reached KRW 17.7 bn (YoY 41%) in gross profit.



As continuous sales growth of devices with lower COGS ratio such as HIFU, RF and Consumables ,
both the cost-of-sales ratio and the gross sales ratio remained stable.



III. Operating profit

With high sales growth, the SG&A ratio decreased and reported operating profit of KRW 8.5bn (YoY 73%)
and its operating profit ratio was 34%.

the SG&A costs increased by KRW 1.5 billion compared to the same last year, including the recruitment for R&D
the related cost of launching new product, and the R&D costs.



IV. Net profit

With high sales growth and cost control, the net profit reverted to a surplus of KRW 6.5bn in the first quarter 2022.

In the first quarter of 2021, the merger cost reached KRW 10.5 bn, which led to a quarterly loss of KRW 6.3 bn, but it was reflected of one-off costs.

► Consolidated Statements of Income (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	1Q 2022	1Q 2021	4Q 2021	YoY	QoQ
Sales	25,334,283,272	17,257,828,940	24,394,945,313	46.8%	3.9%
Cost of sales	7,638,226,900	4,712,298,010	7,997,763,892	62.1%	-4.5%
Gross profit	17,696,056,372	12,545,530,930	16,397,181,421	41.1%	7.9%
SG&A	9,147,281,020	7,612,953,671	9,784,443,630	20.2%	-6.5%
Operating profit	8,548,775,352	4,932,577,259	6,612,737,791	73.3%	29.3%
Profit before tax	8,399,171,854	- 5,657,023,189	6,612,955,230	Turnaround	27.0%
Net Profit	6,512,176,555	- 6,303,094,912	8,026,423,939	Turnaround	-18.9%